Brave New World!

COBO Technologies and BioXpedia partner to develop and advance a new platform for Quality Control of CRISPR-edited cells. This platform is aimed at supporting the clinical development of future therapies using gene-editing tools such as CRISPR.

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. Also there is fear that the technology will be difficult to control and will be misused to alter stem cells in humans at the pre-fetal stage. CRISPR/Cas9 is a system found in bacteria and involved in immune defence. Bacteria use CRISPR/Cas9 to cut up the DNA of invading bacterial viruses that might otherwise kill them.

We might want to correct a disease-causing error that was inherited or crept into our DNA when it replicated. Or, in some cases, we may want to enhance the genetic code of crops, livestock or perhaps even people. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell. After that, the next step in CRISPR gene editing is usually to alter that piece of DNA. However, CRISPR has also been adapted to do other things too, such as turning genes on or off without altering their sequence.

However, from time to time error can occur in the gene sequence after editing and that’s where the Danish QA comes into the picture.